New Or­biMed-backed biotech aims to repli­cate Ver­tex's wild­ly suc­cess­ful cys­tic fi­bro­sis pills in oth­er dis­eases

A new biotech aim­ing to tack­le pro­tein mis­fold­ing has land­ed a sub­stan­tial Se­ries A from some blue-chip in­vestors.

Con­gru­ence Ther­a­peu­tics burst on­to the scene Tues­day with a $50 mil­lion round, in­clud­ing funds from Or­biMed. The biotech will use the mon­ey to ad­vance its plat­form and move some of its pro­grams for­ward, CEO Claris­sa Des­jardins told End­points News.

Tues­day’s round was led by Am­pli­tude Ven­tures and Fonds de sol­i­dar­ité FTQ, a pub­lic de­vel­op­ment fund in Que­bec, Cana­da.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER